Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27961047 | 0.88 | CYP1A2 (0.68) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL47090 | 0.86 | CYP1A2 (0.62) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL8593072 | 0.86 | CYP1A2 (0.62) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL5333075 | 0.86 | CYP1A2 (0.66) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL29638033 | 0.84 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL10891708 | 0.84 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL10890268 | 0.84 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL188306 | 0.84 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL3124261 | 0.82 | CYP1A2 (0.67) | CYP1A2TDP1ALDH1A1TSHRGPR35 | |
| SCHEMBL8597496 | 0.82 | CYP1A2 (0.62) | CYP1A2TDP1ALDH1A1TSHRGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925667-B | Ratio type near infrared fluorescent probe molecule and preparation method and application thereof | 复旦大学 | 2024-02-02 | — | — | CN | claimed |
| CN-115925667-A | Ratio type near-infrared fluorescent probe molecule and preparation method and application thereof | 复旦大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115925667-B | Ratio type near infrared fluorescent probe molecule and preparation method and application thereof | 复旦大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-115925667-A | Ratio type near-infrared fluorescent probe molecule and preparation method and application thereof | 复旦大学 | 2023-04-07 | — | — | CN | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| CN-110023315-B | Novel compound or pharmacologically acceptable salt thereof | 国立研究开发法人理化学研究所 | 2021-11-12 | — | — | CN | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-3081612-B1 | PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES | CEMEDINE CO LTD (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-9718999-B2 | Photocurable composition having adhesive properties | CEMEDINE CO., LTD (JP) | 2017-08-01 | — | — | US | disclosed |
| WO-1996040678-A1 | PROCESS FOR THE SYNTHESIS OF BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5569772-A | CHEMICAL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5514826-A | INTERMEDIATES FOR 2-ARYLBENZO(B)THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5512701-A | REACTING SULFOXIDE DERIVATIVE WITH A SILYATING AGENT TO FORM SULFENATE SILYL ESTER, OPTIONALLY REACTING INTERMEDIATE WITH AN AMINE AND/OR A MERCAPTAN | ELI LILLY AND COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| US-5262385-A | Pyrimidine ring containing | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| US-5234951-A | Anti-ulcer agent comprising chalcone derivative | TSUMURA JUNTENDO, INC. (JP) | 1993-08-10 | — | — | US | disclosed |
| US-5106871-A | Reduced side effects | TSUMURA & CO. (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0468766-A1 | Halogen-containing compounds, herbicidal composition containing the same as an active ingredient, and intermediary compounds therefor | Mitsubishi Chemical Corporation (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0292576-A1 | ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES | TSUMURA & CO. (JP) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | CYP1A2 2065/4885TDP1 2936/4885ALDH1A1 115/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | CYP1A2 2758/4885TDP1 2722/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.